234 related articles for article (PubMed ID: 25046371)
1. Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.
Bian EB; Li J; He XJ; Zong G; Jiang T; Li J; Zhao B
Expert Opin Ther Targets; 2014 Oct; 18(10):1197-206. PubMed ID: 25046371
[TBL] [Abstract][Full Text] [Related]
2. LncRNAs: new players in gliomas, with special emphasis on the interaction of lncRNAs With EZH2.
Bian EB; Li J; Xie YS; Zong G; Li J; Zhao B
J Cell Physiol; 2015 Mar; 230(3):496-503. PubMed ID: 24403021
[TBL] [Abstract][Full Text] [Related]
3. Functional roles of enhancer of zeste homolog 2 in gliomas.
Yin Y; Qiu S; Peng Y
Gene; 2016 Jan; 576(1 Pt 2):189-94. PubMed ID: 26435191
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
5. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
[TBL] [Abstract][Full Text] [Related]
6. Circ-EZH2 knockdown reverses DDAH1 and CBX3-mediated cell growth and invasion in glioma through miR-1265 sponge activity.
Gao F; Du Y; Zhang Y; Ren D; Xu J; Chen D
Gene; 2020 Feb; 726():144196. PubMed ID: 31669648
[TBL] [Abstract][Full Text] [Related]
7. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
8. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
9. [Genetic and epigenetic markers of gliomas].
Semenova EV; Filatov MV
Tsitologiia; 2013; 55(5):290-9. PubMed ID: 24592735
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
11. DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression.
Ning X; Shi Z; Liu X; Zhang A; Han L; Jiang K; Kang C; Zhang Q
Cancer Lett; 2015 Apr; 359(2):198-205. PubMed ID: 25595591
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
14. EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M; Rubio C; Segovia C; López-Calderón FF; Dueñas M; Paramio JM
Int J Mol Sci; 2015 Nov; 16(11):27107-32. PubMed ID: 26580594
[TBL] [Abstract][Full Text] [Related]
15. EZH2 as a potential target in cancer therapy.
McCabe MT; Creasy CL
Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
[TBL] [Abstract][Full Text] [Related]
16. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of enhancer of zests homolog 2 in lymphoma.
Guo SQ; Zhang YZ
Chin Med J (Engl); 2012 Oct; 125(20):3735-9. PubMed ID: 23075734
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
19. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
20. EZH2, an epigenetic driver of prostate cancer.
Yang YA; Yu J
Protein Cell; 2013 May; 4(5):331-41. PubMed ID: 23636686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
